Vaccine effectiveness of CoronaVac against COVID-19 among children in Brazil during the Omicron period

Pilar T. V. Florentino (), Flávia J. O. Alves, Thiago Cerqueira-Silva, Vinicius de Araújo Oliveira, Juracy B. S. Júnior, Adelson G. Jantsch, Gerson O. Penna, Viviane Boaventura, Guilherme L. Werneck, Laura C. Rodrigues, Neil Pearce, Manoel Barral-Netto, Mauricio L. Barreto and Enny S. Paixão
Additional contact information
Pilar T. V. Florentino: Oswaldo Cruz Foundation (Fiocruz)
Flávia J. O. Alves: Oswaldo Cruz Foundation (Fiocruz)
Thiago Cerqueira-Silva: Oswaldo Cruz Foundation (Fiocruz)
Vinicius de Araújo Oliveira: Oswaldo Cruz Foundation (Fiocruz)
Juracy B. S. Júnior: Federal University of Bahia
Adelson G. Jantsch: Oswaldo Cruz Foundation (Fiocruz)
Gerson O. Penna: University of Brasília, Fiocruz School of Government
Viviane Boaventura: Oswaldo Cruz Foundation (Fiocruz)
Guilherme L. Werneck: State University of Rio de Janeiro
Laura C. Rodrigues: London School of Hygiene and Tropical Medicine
Neil Pearce: London School of Hygiene and Tropical Medicine
Manoel Barral-Netto: Oswaldo Cruz Foundation (Fiocruz)
Mauricio L. Barreto: Oswaldo Cruz Foundation (Fiocruz)
Enny S. Paixão: London School of Hygiene and Tropical Medicine

Nature Communications, 2022, vol. 13, issue 1, 1-5

Abstract: Abstract Although severe COVID-19 in children is rare, they may develop multisystem inflammatory syndrome, long-COVID and downstream effects of COVID-19, including social isolation and disruption of education. Data on the effectiveness of the CoronaVac vaccine is scarce during the Omicron period. In Brazil, children between 6 to 11 years are eligible to receive the CoronaVac vaccine. We conducted a test-negative design to estimate vaccine effectiveness using 197,958 tests from January 21, 2022, to April 15, 2022, during the Omicron dominant period in Brazil among children aged 6 to 11 years. The estimated vaccine effectiveness for symptomatic infection was 39.8% (95% CI 33.7–45.4) at ≥14 days post-second dose. For hospital admission vaccine effectiveness was 59.2% (95% CI 11.3–84.5) at ≥14 days. Two doses of CoronaVac in children during the Omicron period showed low levels of protection against symptomatic infection, and modest levels against severe illness.

Date: 2022
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-022-32524-5 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:13:y:2022:i:1:d:10.1038_s41467-022-32524-5

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-022-32524-5

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().